Free Trial

NeuroPace (NPCE) Financials

NeuroPace logo
$10.79 +0.36 (+3.45%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$10.79 0.00 (0.00%)
As of 04/17/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for NeuroPace

Annual Income Statements for NeuroPace

This table shows NeuroPace's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-47 -33 -27
Consolidated Net Income / (Loss)
-47 -33 -27
Net Income / (Loss) Continuing Operations
-47 -33 -27
Total Pre-Tax Income
-47 -33 -27
Total Operating Income
-41 -27 -22
Total Gross Profit
32 48 59
Total Revenue
46 65 80
Operating Revenue
46 65 80
Total Cost of Revenue
13 17 21
Operating Cost of Revenue
13 17 21
Total Operating Expenses
73 75 81
Selling, General & Admin Expense
51 55 57
Research & Development Expense
22 21 24
Total Other Income / (Expense), net
-6.29 -5.78 -5.47
Interest Expense
7.53 8.52 8.80
Interest & Investment Income
1.58 3.05 3.02
Other Income / (Expense), net
-0.34 -0.32 0.30
Basic Earnings per Share
($1.91) ($1.27) ($0.93)
Weighted Average Basic Shares Outstanding
24.59M 25.85M 29.13M
Diluted Earnings per Share
($1.91) ($1.27) ($0.93)
Weighted Average Diluted Shares Outstanding
24.59M 25.85M 29.13M
Weighted Average Basic & Diluted Shares Outstanding
25.10M 28.34M 32.56M
Cash Dividends to Common per Share
- $0.00 $0.00

Quarterly Income Statements for NeuroPace

This table shows NeuroPace's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-12 -11 -10 -9.12 -7.26 -6.20 -8.93 -7.51 -5.45 -5.25
Consolidated Net Income / (Loss)
-12 -11 -10 -9.12 -7.26 -6.20 -8.93 -7.51 -5.45 -5.25
Net Income / (Loss) Continuing Operations
-12 -11 -10 -9.12 -7.26 -6.20 -8.93 -7.51 -5.45 -5.25
Total Pre-Tax Income
-12 -11 -10 -9.12 -7.26 -6.20 -8.93 -7.51 -5.45 -5.25
Total Operating Income
-10 -9.86 -8.32 -7.85 -5.95 -5.05 -7.55 -6.23 -4.24 -3.65
Total Gross Profit
7.97 8.80 10 12 12 14 13 14 15 16
Total Revenue
11 13 14 17 16 18 18 19 21 21
Operating Revenue
11 13 14 17 16 18 18 19 21 21
Total Cost of Revenue
3.19 3.99 4.10 4.54 4.19 4.47 4.78 5.12 5.64 5.28
Operating Cost of Revenue
3.19 3.99 4.10 4.54 4.19 4.47 4.78 5.12 5.64 5.28
Total Operating Expenses
18 19 19 20 18 19 21 20 20 20
Selling, General & Admin Expense
13 14 13 14 13 13 15 14 14 14
Research & Development Expense
5.61 5.09 5.26 5.34 4.80 5.38 5.78 6.07 5.75 6.05
Total Other Income / (Expense), net
-1.59 -1.29 -2.06 -1.27 -1.31 -1.15 -1.38 -1.28 -1.21 -1.60
Interest Expense
1.91 1.94 1.97 2.13 2.19 2.24 2.26 2.17 2.18 2.19
Interest & Investment Income
0.42 0.80 0.73 0.73 0.77 0.82 0.83 0.76 0.75 0.68
Other Income / (Expense), net
-0.10 -0.15 -0.82 0.12 0.12 0.27 0.05 0.12 0.22 -0.09
Basic Earnings per Share
($0.48) ($0.44) ($0.41) ($0.36) ($0.28) ($0.22) ($0.32) ($0.26) ($0.19) ($0.16)
Weighted Average Basic Shares Outstanding
24.73M 24.59M 25.10M 25.47M 26.02M 25.85M 28.29M 28.85M 29.44M 29.13M
Diluted Earnings per Share
($0.48) ($0.44) ($0.41) ($0.36) ($0.28) ($0.22) ($0.32) ($0.26) ($0.19) ($0.16)
Weighted Average Diluted Shares Outstanding
24.73M 24.59M 25.10M 25.47M 26.02M 25.85M 28.29M 28.85M 29.44M 29.13M
Weighted Average Basic & Diluted Shares Outstanding
24.90M 25.10M 25.41M 25.86M 26.28M 28.34M 28.77M 29.20M 29.85M 32.56M

Annual Cash Flow Statements for NeuroPace

This table details how cash moves in and out of NeuroPace's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-13 11 -4.63
Net Cash From Operating Activities
-37 -20 -18
Net Cash From Continuing Operating Activities
-37 -20 -18
Net Income / (Loss) Continuing Operations
-47 -33 -27
Consolidated Net Income / (Loss)
-47 -33 -27
Depreciation Expense
0.27 0.17 0.21
Amortization Expense
2.98 1.72 1.79
Non-Cash Adjustments To Reconcile Net Income
12 12 13
Changes in Operating Assets and Liabilities, net
-4.79 -1.07 -5.45
Net Cash From Investing Activities
24 23 8.99
Net Cash From Continuing Investing Activities
24 23 8.99
Purchase of Property, Plant & Equipment
-0.60 -0.17 -0.31
Sale and/or Maturity of Investments
24 23 9.30
Net Cash From Financing Activities
0.49 8.13 4.33
Net Cash From Continuing Financing Activities
0.49 8.13 4.33
Repurchase of Common Equity
-0.35 -0.31 0.00
Issuance of Common Equity
0.90 8.69 5.21
Other Financing Activities, net
-0.06 -0.26 -0.88
Cash Interest Paid
4.46 4.48 6.23

Quarterly Cash Flow Statements for NeuroPace

This table details how cash moves in and out of NeuroPace's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-0.01 0.92 0.12 1.14 1.86 8.34 -5.06 -0.15 2.57 -1.99
Net Cash From Operating Activities
-6.98 -7.84 -9.70 -4.36 -2.30 -3.34 -7.53 -3.90 -1.72 -4.80
Net Cash From Continuing Operating Activities
-6.98 -7.84 -9.70 -4.36 -2.30 -3.34 -7.53 -3.90 -1.72 -4.80
Net Income / (Loss) Continuing Operations
-12 -11 -10 -9.12 -7.26 -6.20 -8.93 -7.51 -5.45 -5.25
Consolidated Net Income / (Loss)
-12 -11 -10 -9.12 -7.26 -6.20 -8.93 -7.51 -5.45 -5.25
Depreciation Expense
0.06 0.05 0.05 0.05 0.04 0.04 0.05 0.06 0.06 0.05
Amortization Expense
0.74 0.76 0.41 0.42 0.44 0.45 0.46 0.44 0.44 0.45
Non-Cash Adjustments To Reconcile Net Income
3.19 3.15 3.86 2.82 4.00 1.75 3.54 3.47 2.68 2.96
Changes in Operating Assets and Liabilities, net
0.82 -0.67 -3.64 1.47 0.48 0.62 -2.65 -0.35 0.55 -3.00
Net Cash From Investing Activities
6.97 8.90 10 5.30 4.19 3.47 2.40 3.24 1.40 1.96
Net Cash From Continuing Investing Activities
6.97 8.90 10 5.30 4.19 3.47 2.40 3.24 1.40 1.96
Purchase of Property, Plant & Equipment
-0.03 -0.10 -0.13 - -0.01 -0.03 -0.10 -0.06 -0.10 -0.04
Sale and/or Maturity of Investments
7.00 9.00 10 5.30 4.20 3.50 2.50 3.30 1.50 2.00
Net Cash From Financing Activities
-0.01 -0.14 -0.26 0.20 -0.03 8.21 0.07 0.51 2.90 0.85
Net Cash From Continuing Financing Activities
-0.01 -0.14 -0.26 0.20 -0.03 8.21 0.07 0.51 2.90 0.85
Issuance of Common Equity
- 0.21 0.00 0.25 0.01 8.44 0.72 0.58 0.03 3.87
Other Financing Activities, net
-0.01 -0.00 -0.15 -0.04 -0.04 -0.04 -0.65 -0.07 2.86 -3.02
Cash Interest Paid
0.97 0.98 1.02 1.13 1.16 1.17 1.17 1.19 1.93 1.93

Annual Balance Sheets for NeuroPace

This table presents NeuroPace's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
114 108 95
Total Current Assets
98 93 81
Cash & Equivalents
6.61 18 13
Short-Term Investments
71 48 39
Accounts Receivable
7.48 12 13
Inventories, net
9.71 11 13
Prepaid Expenses
3.11 2.74 2.35
Plant, Property, & Equipment, net
1.06 1.00 1.05
Total Noncurrent Assets
15 14 12
Other Noncurrent Operating Assets
15 14 12
Total Liabilities & Shareholders' Equity
114 108 95
Total Liabilities
79 87 87
Total Current Liabilities
11 16 15
Accounts Payable
2.15 2.33 2.95
Accrued Expenses
7.41 11 9.79
Current Deferred Revenue
0.00 1.09 0.56
Other Current Liabilities
1.42 1.63 1.86
Total Noncurrent Liabilities
68 71 71
Long-Term Debt
53 57 60
Other Noncurrent Operating Liabilities
15 14 12
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
35 21 8.01
Total Preferred & Common Equity
35 21 8.01
Preferred Stock
0.00 0.00 0.00
Total Common Equity
35 21 8.01
Common Stock
507 524 539
Retained Earnings
-471 -504 -531

Quarterly Balance Sheets for NeuroPace

This table presents NeuroPace's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
120 106 102 99 99 94 96
Total Current Assets
104 90 87 84 84 80 83
Cash & Equivalents
5.69 6.72 7.86 9.72 13 13 15
Short-Term Investments
80 61 56 52 46 43 41
Accounts Receivable
7.88 9.19 11 11 12 11 12
Inventories, net
8.58 11 10 9.76 11 11 12
Prepaid Expenses
2.50 2.60 2.05 1.59 2.26 2.08 2.12
Plant, Property, & Equipment, net
0.89 1.02 0.98 0.95 1.05 1.00 1.04
Total Noncurrent Assets
15 15 15 14 14 13 13
Other Noncurrent Operating Assets
15 15 15 14 14 13 13
Total Liabilities & Shareholders' Equity
120 106 102 99 99 94 96
Total Liabilities
77 79 81 83 85 85 86
Total Current Liabilities
9.42 9.88 12 13 13 13 15
Accounts Payable
1.18 1.83 1.81 1.21 3.27 2.29 2.16
Accrued Expenses
7.55 6.58 8.18 10 7.29 7.75 10
Current Deferred Revenue
- - - - 0.87 0.81 0.75
Other Current Liabilities
0.69 1.47 1.52 1.57 1.68 1.74 1.80
Total Noncurrent Liabilities
68 69 69 70 71 72 72
Long-Term Debt
52 54 55 56 58 59 59
Other Noncurrent Operating Liabilities
16 15 15 14 13 13 12
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
43 27 21 16 14 9.89 9.82
Total Preferred & Common Equity
43 27 21 16 14 9.89 9.82
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
43 27 21 16 14 9.89 9.82
Common Stock
504 509 512 514 527 530 536
Retained Earnings
-460 -481 -490 -498 -513 -520 -526

Annual Metrics and Ratios for NeuroPace

This table displays calculated financial ratios and metrics derived from NeuroPace's official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
0.75% 43.72% 22.14%
EBITDA Growth
-32.68% 32.43% 24.34%
EBIT Growth
-41.26% 33.17% 22.27%
NOPAT Growth
-71.86% 33.39% 20.25%
Net Income Growth
-30.49% 30.00% 17.64%
EPS Growth
11.98% 33.51% 26.77%
Operating Cash Flow Growth
-50.01% 46.56% 8.89%
Free Cash Flow Firm Growth
-94.11% 35.97% 5.51%
Invested Capital Growth
32.38% 8.49% 32.54%
Revenue Q/Q Growth
4.10% 8.68% 4.52%
EBITDA Q/Q Growth
-0.84% 16.03% 5.20%
EBIT Q/Q Growth
-2.46% 15.96% 4.67%
NOPAT Q/Q Growth
-2.11% 15.03% 6.06%
Net Income Q/Q Growth
-0.97% 13.05% 3.38%
EPS Q/Q Growth
-106.39% 14.77% 6.06%
Operating Cash Flow Q/Q Growth
0.97% 18.60% -8.83%
Free Cash Flow Firm Q/Q Growth
-3.72% 14.76% -7.40%
Invested Capital Q/Q Growth
3.32% 2.29% 20.59%
Profitability Metrics
- - -
Gross Margin
71.38% 73.56% 73.94%
EBITDA Margin
-83.23% -39.13% -24.24%
Operating Margin
-89.62% -41.54% -27.12%
EBIT Margin
-90.36% -42.02% -26.74%
Profit (Net Income) Margin
-103.43% -50.38% -33.97%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
114.47% 119.89% 127.02%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-316.46% -177.48% -116.97%
ROIC Less NNEP Spread (ROIC-NNEP)
-275.40% -95.51% 760.04%
Return on Net Nonoperating Assets (RNNOA)
229.50% 58.58% -72.38%
Return on Equity (ROE)
-86.96% -118.91% -189.35%
Cash Return on Invested Capital (CROIC)
-344.33% -185.63% -144.96%
Operating Return on Assets (OROA)
-33.21% -24.79% -21.12%
Return on Assets (ROA)
-38.02% -29.72% -26.83%
Return on Common Equity (ROCE)
-86.96% -118.91% -189.35%
Return on Equity Simple (ROE_SIMPLE)
-135.38% -159.56% -338.71%
Net Operating Profit after Tax (NOPAT)
-29 -19 -15
NOPAT Margin
-62.73% -29.08% -18.98%
Net Nonoperating Expense Percent (NNEP)
-41.06% -81.98% -877.02%
Return On Investment Capital (ROIC_SIMPLE)
- -24.51% -22.46%
Cost of Revenue to Revenue
28.62% 26.44% 26.06%
SG&A Expenses to Revenue
112.79% 83.33% 71.46%
R&D to Revenue
48.21% 31.76% 29.60%
Operating Expenses to Revenue
161.00% 115.09% 101.06%
Earnings before Interest and Taxes (EBIT)
-41 -27 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-38 -26 -19
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.07 13.12 41.68
Price to Tangible Book Value (P/TBV)
1.07 13.12 41.68
Price to Revenue (P/Rev)
0.82 4.14 4.18
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.23 23.44 23.05
Enterprise Value to Revenue (EV/Rev)
0.28 4.00 4.26
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
1.52 2.76 7.43
Long-Term Debt to Equity
1.52 2.76 7.43
Financial Leverage
-0.83 -0.61 -0.10
Leverage Ratio
2.29 4.00 7.06
Compound Leverage Factor
2.62 4.80 8.96
Debt to Total Capital
60.34% 73.39% 88.14%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
60.34% 73.39% 88.14%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
39.66% 26.61% 11.86%
Debt to EBITDA
-1.40 -2.22 -3.07
Net Debt to EBITDA
0.65 0.37 -0.35
Long-Term Debt to EBITDA
-1.40 -2.22 -3.07
Debt to NOPAT
-1.85 -2.99 -3.92
Net Debt to NOPAT
0.86 0.50 -0.45
Long-Term Debt to NOPAT
-1.85 -2.99 -3.92
Altman Z-Score
-5.37 -4.07 -4.60
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
8.90 5.71 5.37
Quick Ratio
7.73 4.85 4.33
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-31 -20 -19
Operating Cash Flow to CapEx
-6,114.26% -11,387.86% -5,865.69%
Free Cash Flow to Firm to Interest Expense
-4.13 -2.34 -2.14
Operating Cash Flow to Interest Expense
-4.90 -2.31 -2.04
Operating Cash Flow Less CapEx to Interest Expense
-4.98 -2.33 -2.07
Efficiency Ratios
- - -
Asset Turnover
0.37 0.59 0.79
Accounts Receivable Turnover
6.25 6.61 6.35
Inventory Turnover
1.49 1.65 1.69
Fixed Asset Turnover
54.61 63.30 77.77
Accounts Payable Turnover
7.39 7.72 7.88
Days Sales Outstanding (DSO)
58.43 55.22 57.48
Days Inventory Outstanding (DIO)
245.64 220.76 215.58
Days Payable Outstanding (DPO)
49.38 47.25 46.33
Cash Conversion Cycle (CCC)
254.68 228.74 226.72
Capital & Investment Metrics
- - -
Invested Capital
10 11 15
Invested Capital Turnover
5.04 6.10 6.16
Increase / (Decrease) in Invested Capital
2.52 0.87 3.63
Enterprise Value (EV)
13 261 341
Market Capitalization
37 271 334
Book Value per Share
$1.40 $0.79 $0.27
Tangible Book Value per Share
$1.40 $0.79 $0.27
Total Capital
88 78 68
Total Debt
53 57 60
Total Long-Term Debt
53 57 60
Net Debt
-24 -9.50 6.77
Capital Expenditures (CapEx)
0.60 0.17 0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)
9.33 10 13
Debt-free Net Working Capital (DFNWC)
87 76 66
Net Working Capital (NWC)
87 76 66
Net Nonoperating Expense (NNE)
19 14 12
Net Nonoperating Obligations (NNO)
-24 -9.50 6.77
Total Depreciation and Amortization (D&A)
3.25 1.89 2.00
Debt-free, Cash-free Net Working Capital to Revenue
20.49% 15.34% 16.80%
Debt-free Net Working Capital to Revenue
190.55% 116.92% 82.83%
Net Working Capital to Revenue
190.55% 116.92% 82.83%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.91) ($1.27) ($0.93)
Adjusted Weighted Average Basic Shares Outstanding
24.59M 25.85M 29.13M
Adjusted Diluted Earnings per Share
($1.91) ($1.27) ($0.93)
Adjusted Weighted Average Diluted Shares Outstanding
24.59M 25.85M 29.13M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.10M 28.34M 32.56M
Normalized Net Operating Profit after Tax (NOPAT)
-29 -19 -15
Normalized NOPAT Margin
-62.73% -29.08% -18.98%
Pre Tax Income Margin
-103.43% -50.38% -33.97%
Debt Service Ratios
- - -
EBIT to Interest Expense
-5.46 -3.23 -2.43
NOPAT to Interest Expense
-3.79 -2.23 -1.72
EBIT Less CapEx to Interest Expense
-5.54 -3.25 -2.46
NOPAT Less CapEx to Interest Expense
-3.87 -2.25 -1.76
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.74% -0.93% 0.00%

Quarterly Metrics and Ratios for NeuroPace

This table displays calculated financial ratios and metrics derived from NeuroPace's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
7.91% 16.30% 27.24% 61.86% 47.23% 40.84% 25.23% 16.63% 28.20% 19.18%
EBITDA Growth
-51.74% -3.56% 3.01% 29.20% 43.54% 53.18% 19.41% 22.70% 34.25% 24.69%
EBIT Growth
-61.15% -10.96% 6.44% 30.08% 43.36% 52.16% 17.97% 20.98% 31.04% 21.88%
NOPAT Growth
-63.37% -9.36% 14.78% 28.43% 41.66% 48.77% 9.30% 20.68% 28.69% 27.68%
Net Income Growth
-45.80% -4.24% 9.48% 28.10% 38.42% 44.37% 13.98% 17.65% 24.87% 15.32%
EPS Growth
-41.18% -101.40% 12.77% 30.77% 41.67% 50.00% 21.95% 27.78% 32.14% 27.27%
Operating Cash Flow Growth
-57.66% 4.39% 14.88% 59.09% 67.00% 57.40% 22.38% 10.55% 25.11% -43.58%
Free Cash Flow Firm Growth
25.95% -65.15% -8.95% 28.49% 43.94% 53.18% 49.13% 19.73% 15.49% -40.32%
Invested Capital Growth
25.01% 32.38% 40.67% 8.69% 9.58% 8.49% -2.18% 6.84% 12.43% 32.54%
Revenue Q/Q Growth
9.38% 14.63% 13.16% 14.08% -0.50% 9.65% 0.62% 6.25% 9.37% 1.93%
EBITDA Q/Q Growth
7.36% 3.28% 5.55% 16.33% 26.13% 19.80% -62.59% 19.75% 37.17% 8.14%
EBIT Q/Q Growth
6.85% 2.88% 8.69% 15.37% 24.53% 17.98% -56.58% 18.47% 34.14% 7.08%
NOPAT Q/Q Growth
7.06% 3.33% 15.62% 5.59% 24.24% 15.11% -49.38% 17.43% 31.89% 13.91%
Net Income Q/Q Growth
7.13% 5.42% 6.92% 12.06% 20.46% 14.57% -43.95% 15.81% 27.44% 3.71%
EPS Q/Q Growth
7.69% 8.33% 6.82% 12.20% 22.22% 21.43% -45.45% 18.75% 26.92% 15.79%
Operating Cash Flow Q/Q Growth
34.56% -12.44% -23.65% 55.04% 47.20% -45.13% -125.32% 48.19% 55.79% -178.25%
Free Cash Flow Firm Q/Q Growth
-0.48% -3.13% -4.01% 33.66% 21.23% 13.86% -13.02% -4.69% 17.08% -43.03%
Invested Capital Q/Q Growth
-13.54% 3.32% 33.59% -8.92% -12.83% 2.29% 20.45% -0.53% -8.27% 20.59%
Profitability Metrics
- - - - - - - - - -
Gross Margin
71.39% 68.83% 71.67% 72.51% 74.47% 75.20% 73.62% 73.40% 73.22% 75.41%
EBITDA Margin
-85.14% -71.84% -59.96% -43.97% -32.65% -23.88% -38.58% -29.14% -16.74% -15.09%
Operating Margin
-91.41% -77.09% -57.48% -47.57% -36.22% -28.04% -41.63% -32.35% -20.15% -17.02%
EBIT Margin
-92.34% -78.23% -63.13% -46.83% -35.52% -26.57% -41.35% -31.73% -19.11% -17.42%
Profit (Net Income) Margin
-105.63% -87.15% -71.69% -55.26% -44.18% -34.42% -49.24% -39.02% -25.89% -24.46%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
114.40% 111.40% 113.56% 118.00% 124.37% 129.54% 119.10% 122.98% 135.49% 140.41%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-312.45% -272.22% -166.52% -152.31% -146.37% -119.82% -148.17% -125.73% -93.10% -73.40%
ROIC Less NNEP Spread (ROIC-NNEP)
-303.78% -262.81% -152.89% -137.84% -130.48% -104.15% -98.47% -5.34% 71.10% 123.88%
Return on Net Nonoperating Assets (RNNOA)
260.30% 219.01% 113.11% 93.18% 84.96% 63.87% 34.52% 0.90% -8.21% -11.80%
Return on Equity (ROE)
-52.15% -53.21% -53.40% -59.13% -61.42% -55.95% -113.66% -124.83% -101.31% -85.20%
Cash Return on Invested Capital (CROIC)
-334.50% -344.33% -268.26% -219.52% -223.84% -185.63% -133.84% -140.67% -151.13% -144.96%
Operating Return on Assets (OROA)
-30.85% -28.76% -26.09% -23.30% -19.46% -15.68% -27.85% -23.18% -14.94% -13.76%
Return on Assets (ROA)
-35.30% -32.04% -29.63% -27.50% -24.20% -20.31% -33.16% -28.51% -20.24% -19.32%
Return on Common Equity (ROCE)
-52.15% -53.21% -53.40% -59.13% -61.42% -55.95% -113.66% -124.83% -101.31% -85.20%
Return on Equity Simple (ROE_SIMPLE)
-107.42% 0.00% -167.32% -199.90% -231.63% 0.00% -219.69% -302.44% -285.97% 0.00%
Net Operating Profit after Tax (NOPAT)
-7.14 -6.90 -5.82 -5.50 -4.17 -3.54 -5.28 -4.36 -2.97 -2.56
NOPAT Margin
-63.99% -53.96% -40.24% -33.30% -25.35% -19.63% -29.14% -22.65% -14.10% -11.91%
Net Nonoperating Expense Percent (NNEP)
-8.67% -9.41% -13.62% -14.47% -15.89% -15.67% -49.70% -120.39% -164.20% -197.28%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -4.56% - - - -3.79%
Cost of Revenue to Revenue
28.61% 31.17% 28.33% 27.49% 25.53% 24.80% 26.38% 26.60% 26.78% 24.59%
SG&A Expenses to Revenue
112.51% 106.13% 92.79% 87.72% 81.50% 73.39% 83.34% 74.26% 66.04% 64.25%
R&D to Revenue
50.29% 39.79% 36.37% 32.36% 29.19% 29.85% 31.91% 31.50% 27.32% 28.18%
Operating Expenses to Revenue
162.80% 145.92% 129.15% 120.08% 110.69% 103.24% 115.25% 105.75% 93.37% 92.43%
Earnings before Interest and Taxes (EBIT)
-10 -10 -9.14 -7.73 -5.84 -4.79 -7.49 -6.11 -4.02 -3.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.50 -9.19 -8.68 -7.26 -5.36 -4.30 -6.99 -5.61 -3.53 -3.24
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.15 1.07 4.24 5.37 15.38 13.12 26.09 22.00 20.72 41.68
Price to Tangible Book Value (P/TBV)
2.15 1.07 4.24 5.37 15.38 13.12 26.09 22.00 20.72 41.68
Price to Revenue (P/Rev)
2.13 0.82 2.40 2.08 4.18 4.14 5.42 3.03 2.66 4.18
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
6.00 1.23 7.48 8.42 22.57 23.44 27.78 16.53 16.80 23.05
Enterprise Value to Revenue (EV/Rev)
1.37 0.28 2.11 1.92 4.09 4.00 5.40 3.08 2.69 4.26
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
1.20 1.52 1.96 2.58 3.42 2.76 4.05 5.97 6.03 7.43
Long-Term Debt to Equity
1.20 1.52 1.96 2.58 3.42 2.76 4.05 5.97 6.03 7.43
Financial Leverage
-0.86 -0.83 -0.74 -0.68 -0.65 -0.61 -0.35 -0.17 -0.12 -0.10
Leverage Ratio
2.09 2.29 2.60 2.98 3.68 4.00 4.90 6.32 7.47 7.06
Compound Leverage Factor
2.39 2.55 2.96 3.51 4.57 5.18 5.84 7.77 10.12 9.91
Debt to Total Capital
54.48% 60.34% 66.21% 72.10% 77.35% 73.39% 80.19% 85.65% 85.78% 88.14%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
54.48% 60.34% 66.21% 72.10% 77.35% 73.39% 80.19% 85.65% 85.78% 88.14%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
45.52% 39.66% 33.79% 27.90% 22.65% 26.61% 19.81% 14.35% 14.22% 11.86%
Debt to EBITDA
-1.38 -1.40 -1.43 -1.58 -1.83 -2.22 -2.43 -2.65 -2.90 -3.07
Net Debt to EBITDA
0.89 0.65 0.37 0.25 0.18 0.37 0.04 -0.16 -0.12 -0.35
Long-Term Debt to EBITDA
-1.38 -1.40 -1.43 -1.58 -1.83 -2.22 -2.43 -2.65 -2.90 -3.07
Debt to NOPAT
-1.86 -1.85 -1.96 -2.16 -2.50 -2.99 -3.14 -3.40 -3.67 -3.92
Net Debt to NOPAT
1.20 0.86 0.50 0.34 0.24 0.50 0.05 -0.20 -0.15 -0.45
Long-Term Debt to NOPAT
-1.86 -1.85 -1.96 -2.16 -2.50 -2.99 -3.14 -3.40 -3.67 -3.92
Altman Z-Score
-3.59 -4.47 -4.37 -4.70 -3.92 -3.37 -3.29 -4.77 -4.73 -3.99
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
11.08 8.90 9.13 7.52 6.55 5.71 6.43 6.37 5.59 5.37
Quick Ratio
9.91 7.73 7.78 6.47 5.67 4.85 5.38 5.31 4.63 4.33
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-9.13 -9.42 -9.79 -6.50 -5.12 -4.41 -4.98 -5.22 -4.33 -6.19
Operating Cash Flow to CapEx
-22,500.00% -7,689.22% -7,346.97% 0.00% -25,577.78% -10,440.63% -7,238.46% -6,190.48% -1,724.00% -12,300.00%
Free Cash Flow to Firm to Interest Expense
-4.79 -4.85 -4.98 -3.06 -2.34 -1.97 -2.21 -2.41 -1.98 -2.82
Operating Cash Flow to Interest Expense
-3.66 -4.04 -4.94 -2.05 -1.05 -1.49 -3.33 -1.80 -0.79 -2.19
Operating Cash Flow Less CapEx to Interest Expense
-3.68 -4.09 -5.00 -2.05 -1.05 -1.51 -3.38 -1.83 -0.84 -2.21
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.33 0.37 0.41 0.50 0.55 0.59 0.67 0.73 0.78 0.79
Accounts Receivable Turnover
6.04 6.25 5.33 5.68 6.29 6.61 6.63 6.49 6.69 6.35
Inventory Turnover
1.52 1.49 1.49 1.72 1.83 1.65 1.62 1.74 1.83 1.69
Fixed Asset Turnover
57.61 54.61 51.61 57.01 65.33 63.30 66.67 72.76 76.84 77.77
Accounts Payable Turnover
9.85 7.39 6.91 9.56 14.12 7.72 7.06 9.06 11.89 7.88
Days Sales Outstanding (DSO)
60.46 58.43 68.52 64.29 58.07 55.22 55.02 56.20 54.52 57.48
Days Inventory Outstanding (DIO)
240.19 245.64 245.55 212.70 199.02 220.76 224.99 210.15 199.22 215.58
Days Payable Outstanding (DPO)
37.06 49.38 52.84 38.19 25.85 47.25 51.74 40.28 30.71 46.33
Cash Conversion Cycle (CCC)
263.59 254.68 261.24 238.79 231.24 228.74 228.28 226.08 223.03 226.72
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
9.95 10 14 13 11 11 13 13 12 15
Invested Capital Turnover
4.88 5.04 4.14 4.57 5.77 6.10 5.08 5.55 6.60 6.16
Increase / (Decrease) in Invested Capital
1.99 2.52 3.97 1.00 0.95 0.87 -0.30 0.86 1.36 3.63
Enterprise Value (EV)
60 13 103 105 246 261 373 221 206 341
Market Capitalization
93 37 116 114 252 271 374 217 204 334
Book Value per Share
$1.75 $1.40 $1.10 $0.84 $0.63 $0.79 $0.51 $0.34 $0.34 $0.27
Tangible Book Value per Share
$1.75 $1.40 $1.10 $0.84 $0.63 $0.79 $0.51 $0.34 $0.34 $0.27
Total Capital
95 88 81 76 72 78 72 69 69 68
Total Debt
52 53 54 55 56 57 58 59 59 60
Total Long-Term Debt
52 53 54 55 56 57 58 59 59 60
Net Debt
-33 -24 -14 -8.72 -5.46 -9.50 -0.91 3.48 2.44 6.77
Capital Expenditures (CapEx)
0.03 0.10 0.13 0.00 0.01 0.03 0.10 0.06 0.10 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)
9.54 9.33 13 11 9.81 10 12 12 11 13
Debt-free Net Working Capital (DFNWC)
95 87 80 75 71 76 71 68 68 66
Net Working Capital (NWC)
95 87 80 75 71 76 71 68 68 66
Net Nonoperating Expense (NNE)
4.65 4.24 4.55 3.63 3.09 2.66 3.64 3.15 2.48 2.69
Net Nonoperating Obligations (NNO)
-33 -24 -14 -8.72 -5.46 -9.50 -0.91 3.48 2.44 6.77
Total Depreciation and Amortization (D&A)
0.80 0.82 0.46 0.47 0.47 0.49 0.50 0.50 0.50 0.50
Debt-free, Cash-free Net Working Capital to Revenue
21.82% 20.49% 26.05% 20.81% 16.30% 15.34% 17.66% 16.85% 14.36% 16.80%
Debt-free Net Working Capital to Revenue
217.14% 190.55% 165.13% 136.55% 118.21% 116.92% 103.00% 94.18% 88.70% 82.83%
Net Working Capital to Revenue
217.14% 190.55% 165.13% 136.55% 118.21% 116.92% 103.00% 94.18% 88.70% 82.83%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.48) ($0.44) ($0.41) ($0.36) ($0.28) ($0.22) ($0.32) ($0.26) ($0.19) ($0.16)
Adjusted Weighted Average Basic Shares Outstanding
24.73M 24.59M 25.10M 25.47M 26.02M 25.85M 28.29M 28.85M 29.44M 29.13M
Adjusted Diluted Earnings per Share
($0.48) ($0.44) ($0.41) ($0.36) ($0.28) ($0.22) ($0.32) ($0.26) ($0.19) ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding
24.73M 24.59M 25.10M 25.47M 26.02M 25.85M 28.29M 28.85M 29.44M 29.13M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
24.90M 25.10M 25.41M 25.86M 26.28M 28.34M 28.77M 29.20M 29.85M 32.56M
Normalized Net Operating Profit after Tax (NOPAT)
-7.14 -6.90 -5.82 -5.50 -4.17 -3.54 -5.28 -4.36 -2.97 -2.56
Normalized NOPAT Margin
-63.99% -53.96% -40.24% -33.30% -25.35% -19.63% -29.14% -22.65% -14.10% -11.91%
Pre Tax Income Margin
-105.63% -87.15% -71.69% -55.26% -44.18% -34.42% -49.24% -39.02% -25.89% -24.46%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-5.41 -5.15 -4.65 -3.64 -2.66 -2.14 -3.32 -2.82 -1.84 -1.71
NOPAT to Interest Expense
-3.75 -3.56 -2.96 -2.59 -1.90 -1.58 -2.34 -2.01 -1.36 -1.17
EBIT Less CapEx to Interest Expense
-5.42 -5.21 -4.72 -3.64 -2.67 -2.15 -3.36 -2.85 -1.89 -1.72
NOPAT Less CapEx to Interest Expense
-3.76 -3.61 -3.03 -2.59 -1.91 -1.60 -2.39 -2.04 -1.41 -1.18
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -0.74% -0.99% -1.10% -1.23% -0.93% -0.62% -0.62% -0.66% 0.00%

Frequently Asked Questions About NeuroPace's Financials

When does NeuroPace's fiscal year end?

According to the most recent income statement we have on file, NeuroPace's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has NeuroPace's net income changed over the last 2 years?

NeuroPace's net income appears to be on a downward trend, with a most recent value of -$27.14 million in 2024, falling from -$47.08 million in 2022. The previous period was -$32.96 million in 2023.

What is NeuroPace's operating income?
NeuroPace's total operating income in 2024 was -$21.67 million, based on the following breakdown:
  • Total Gross Profit: $59.09 million
  • Total Operating Expenses: $80.76 million
How has NeuroPace revenue changed over the last 2 years?

Over the last 2 years, NeuroPace's total revenue changed from $45.52 million in 2022 to $79.91 million in 2024, a change of 75.5%.

How much debt does NeuroPace have?

NeuroPace's total liabilities were at $86.63 million at the end of 2024, a 0.4% decrease from 2023, and a 9.2% increase since 2022.

How much cash does NeuroPace have?

In the past 2 years, NeuroPace's cash and equivalents has ranged from $6.61 million in 2022 to $18.06 million in 2023, and is currently $13.43 million as of their latest financial filing in 2024.

How has NeuroPace's book value per share changed over the last 2 years?

Over the last 2 years, NeuroPace's book value per share changed from 1.40 in 2022 to 0.27 in 2024, a change of -80.8%.



This page (NASDAQ:NPCE) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners